Distinct Sets of Alphabeta TCRs Confer Similar Recognition of Tumor Antigen NY-ESO-1157-165 by Interacting with Its Central Met/Trp Residues
Overview
Authors
Affiliations
Naturally acquired immune responses against human cancers often include CD8(+) T cells specific for the cancer testis antigen NY-ESO-1. Here, we studied T cell receptor (TCR) primary structure and function of 605 HLA-A*0201/NY-ESO-1(157-165)-specific CD8 T cell clones derived from five melanoma patients. We show that an important proportion of tumor-reactive T cells preferentially use TCR AV3S1/BV8S2 chains, with remarkably conserved CDR3 amino acid motifs and lengths in both chains. All remaining T cell clones belong to two additional sets expressing BV1 or BV13 TCRs, associated with alpha-chains with highly diverse VJ usage, CDR3 amino acid sequence, and length. Yet, all T cell clonotypes recognize tumor antigen with similar functional avidity. Two residues, Met-160 and Trp-161, located in the middle region of the NY-ESO-1(157-165) peptide, are critical for recognition by most of the T cell clonotypes. Collectively, our data show that a large number of alphabeta TCRs, belonging to three distinct sets (AVx/BV1, AV3/BV8, AVx/BV13) bind pMHC with equal antigen sensitivity and recognize the same peptide motif. Finally, this in-depth study of recognition of a self-antigen suggests that in part similar biophysical mechanisms shape TCR repertoires toward foreign and self-antigens.
Stefanidis E, Semilietof A, Pujol J, Seijo B, Scholten K, Zoete V J Clin Invest. 2024; 134(11).
PMID: 38828721 PMC: 11142748. DOI: 10.1172/JCI161660.
Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies.
Dobrin A, Lindenbergh P, Shi Y, Perica K, Xie H, Jain N Nat Cancer. 2024; 5(5):760-773.
PMID: 38503896 DOI: 10.1038/s43018-024-00744-x.
Baumgaertner P, Schmidt J, Costa-Nunes C, Bordry N, Guillaume P, Luescher I Front Immunol. 2022; 13:973986.
PMID: 36032094 PMC: 9399405. DOI: 10.3389/fimmu.2022.973986.
STARTRAC analyses of scRNAseq data from tumor models reveal T cell dynamics and therapeutic targets.
Bhatt D, Kang B, Sawant D, Zheng L, Perez K, Huang Z J Exp Med. 2021; 218(6).
PMID: 33900375 PMC: 8077174. DOI: 10.1084/jem.20201329.
Zhang H, Sun M, Wang J, Zeng B, Cao X, Han Y Front Immunol. 2021; 12:644520.
PMID: 33833762 PMC: 8021954. DOI: 10.3389/fimmu.2021.644520.